Fovea Raising Series B

Fovea Pharmaceuticals SA, a Paris-based drug company focused on allergic conjunctivitis, is raising up to Euro 40 million in second-round funding, according to a speech given yesterday by company CFO Bernard Davitian at the Cowen & Co. Healthcare Conference. The news was first reported by VentureWire. The company raised first-round funding in 2005 from firms like Abingworth Management, Credit Agricole Private Equity, GIMV, Wellcome Trust and Sofinnova Partners.